



10A Bukit Pasoh Road
Singapore 089824
t +65 6222 4235
f +65 6225 2419
www.aslanpharma.com

ASLAN Pharmaceuticals opens Taiwan office to support regional development activities

6 February 2014 –ASLAN Pharmaceuticals Pte Ltd, a leading Asia biotech company headquartered in Singapore, announced today the opening of a new office in Taipei, Taiwan. ASLAN currently has 3 drugs in development, and plans to initiate several clinical studies in Taiwan, including a phase 2b program for ASLAN001, a small-molecule pan-HER inhibitor being developed for gastric cancer that showed positive data in a phase 2 study completed last year.

“Taiwan is emerging as a leading centre for conducting high quality clinical trial globally,” said Dr Alan Barge, ASLAN’s Chief Medical Officer. “Strong local talent and experience in global drug development make this an ideal place to develop drugs for global markets.”

Dr Tom Lin, previously Senior Medical Director of OBI Pharma, and Betsy Chiu, previously head of clinical operations for Boehringer Ingelheim Taiwan, have joined ASLAN in Taiwan to support clinical development across the region.

About ASLAN

ASLAN Pharmaceuticals is a specialty pharmaceutical company that develops novel medicines for global markets, headquartered in Singapore. ASLAN licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology and inflammation diseases, and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. ASLAN currently has 3 drugs in clinical development, with the lead compound entering phase 2b for gastric cancer.

For more information, please visit www.aslanpharma.com or contact:

Sean Wong
ASLAN Pharmaceuticals
+65 62224235
media@aslanpharma.com



亞獅康(ASLAN)製藥在台成立辦公室以支持亞洲地區的臨床研發

2014年2月6日

總部位於新加坡的亞洲生技公司亞獅康股份有限公司(ASLAN Pharmaceuticals Pte Ltd)今日宣布在台灣台北市成立新的辦公室。亞獅康目前已有三個藥物在臨床試驗發展階段, 預計在台灣進行數個臨床試驗, 包括了 ASLAN001 第二期 b 階段臨床試驗 (phase IIb), 此新藥是廣泛性表皮生長因子受體的抑制劑, 發展用於胃癌, 並於去年完成的二期試驗中證實有正面的結果。

亞獅康首席醫學長 Alan Barge 醫師表示, 在執行高品質的全球臨床試驗, 台灣是新崛起的領導中心。優秀的當地人才及藥物全球開發的經驗, 使其成了為全球市場開發新藥物的理想地方。

前台灣浩鼎資深醫學處長 Tom Lin 醫師以及前台灣百靈佳股格翰臨床試驗經理 Betsy Chiu 已加入亞獅康以協助亞洲地區的臨床研發。

關於亞獅康 (ASLAN)

亞獅康製藥公司為全球市場研發創新的藥物, 目前總部設立在新加坡。亞獅康自跨國大藥廠取得腫瘤和發炎相關疾病尚未進入臨床試驗或於早期臨床試驗階段的新藥授權, 並透過其在亞洲的高品質及高效率發展資源, 將這些新藥物開發至較後期之臨床試驗。亞獅康目前已有三個藥物在臨床試驗發展階段, 其中胃癌的試驗藥物已經進入第二期 b 階段臨床試驗(phase IIb)。

欲獲得更多資訊, 請參考 www.aslanpharma.com 或聯絡

Sean Wong

亞獅康製藥 (ASLAN Pharmaceuticals)

+65 62224235

media@aslanpharma.com